<DOC>
	<DOCNO>NCT02005120</DOCNO>
	<brief_summary>Malignant pleural effusion ( MPE ) common complication advance non-small cell lung cancer ( NSCLC ) . Bevacizumab , humanize monoclonal antibody vascular endothelial growth factor ( VEGF ) , show efficient suppress accumulation pleural fluid . The widely use treatment MPE recombinant human endostatin .</brief_summary>
	<brief_title>Intrapleural Administration Bevacizumab Versus Endostar Pleural Effusions NSCLC</brief_title>
	<detailed_description>We design clinical trial determine efficacy Safety intrapleural Bevacizumab versus recombinant human endostatin treatment malignant pleural effusion ( MPE ) patient non-small cell lung cancer ( NSCLC ) .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Pleural Effusion</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Endostatins</mesh_term>
	<criteria>Patient confirm stage IV NSCLC malignant pleural effusion confirm cytology . Males female age ≥18 year , &lt; 75 year . Eastern Cooperative Oncology Group ( ECOG ) performance status 03 . Life expectancy ≥12 week . Ability maintain drainage catheter . Previous intrapleural administration chemotherapeutic drug ( preferred bleomycin ) Males females contraceptive period trial 8 week last administration drug . Adequate bone marrow , renal , liver function require . Able comply require protocol followup procedure , able receive oral medication . Institutional review boardapproved informed consent obtain every patient initiation trialspecific procedure treatment . Any unstable systemic disease ( include active infection , uncontrolled hypertension , unstable angina , congestive heart failure , myocardial infarction within previous year , serious cardiac arrhythmia require medication , hepatic , renal , metabolic disease ) . Active thoracic cavity systemic bleeding . Major surgical procedure , open biopsy , significant traumatic injury within 28 day prior day 0 . Female subject pregnant breastfeeding . Known sensitivity Bevacizumab Endostar . Patients must therapeutic anticoagulation warfarin , heparin low molecular weight heparin . Adequate hematological function : Absolute neutrophil count ( ANC ) ≥1.5 x 109/L , Platelet count ≥100 x 109/L . Adequate renal function : Serum creatinine ≤ 1.5 x ULN , ≥ 50 ml/min . Adequate liver function : Total bilirubin £ 1.5 x upper limit normal ( ULN ) Alanine Aminotransferase ( ALT ) Aspartate Aminotransferase ( AST ) &lt; 2.5 x ULN absence liver metastasis , &lt; 5 x ULN case liver metastasis . Patient assess investigator unable unwilling comply requirement protocol .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2013</verification_date>
</DOC>